Lancovutide
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00671736)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cytosolic phospholipase A2INHIBITOR
PLA2G4A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108327 ↗
Also known as
- moli1901
- moli1901
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00671736 | Phase 2 | Oct 1, 2007 | AOP Orphan Pharmaceuticals AG, Medical University of Graz |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AOP Orphan Pharmaceuticals AG | For profit | 1 | 1 | 1 | 2007 |
| Medical University of Graz | Academic/Hospital | 1 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1